Obesity has been suggested as a risk factor for chronic kidney disease. However, it has also been suggested that the association between obesity and impaired glomerular filtration rate (GFR) arises from the invalid use of body surface area (BSA) for scaling. This study assesses the effect of obesity on GFR by comparing the age-dependent decline in obese (body mass index (BMI) 430 kg/m 2 ; n ¼ 149) and non-obese patients (n ¼ 589), aged 430 years, referred for measurement of GFR (Cr-51-EDTA and three blood samples). GFR was scaled to a BSA of 1.73 m 2 (GFR/BSA) and extracellular fluid volume of 13 l (GFR/ECV), both corrected for the one-compartment assumption. When non-obese patients were categorized into 10-year age brackets (from 31 to 470), GFR/BSA and GFR/ECV declined from 92 ml per min per 1.73 m 2 and 95 ml per min per 13 l, respectively, at 31-40 years to 58 and 59 at 470. The declines in obese patients were similar with corresponding values of 88 ml per min per 1.73 m 2 and 97 ml per min per 13 l at 31-40 and 57 and 59 at 470 years. Linear regression analysis of non-categorized data from age 40 years showed rates of decline slightly slower in the obese (0.82 vs 0.95 ml per min per 1.73 m 2 per year and 0.87 vs 1.02 ml per min per 13 l per year). No effect of obesity on renal function was shown. Scaling to BSA did not distort the results.
Introduction
Obesity is associated with several health problems that affect particularly the cardiovascular system, liver and metabolic control. Its impact on the kidneys, however, is less clear, although several studies have shown an adverse effect of body mass index (BMI) on renal risk [1] [2] [3] even in subjects who
were not overtly obese (BMI o30 kg/m 2 ). 4 Adverse effects may also be mediated through comorbid disease more common in the obese, such as cardiovascular disease. 5, 6 One problem encountered in relation to obesity and renal function is that scaling of renal functional parameters, especially glomerular filtration rate (GFR), to body surface area (BSA) is of doubtful validity. Some studies, for instance, showed that when scaled to alternative whole body variables, such as lean body mass, an apparently poorer level of renal function in obese subjects disappeared. 7, 8 Glomerular filtration rate declines with advancing age, 9 although the mechanisms, whether owing to age per se or the result of chronic diseases that are more common in the elderly, are not clear. One way to examine the effect of an adverse health condition on GFR is to look at the age-related decline in GFR in subjects with that condition. The aim of this simple study, therefore, was to compare the agedependent decline in GFR between obese and non-obese subjects. Moreover, in view of doubts concerning the use of BSA for scaling GFR in the obese, GFR was also scaled to extracellular fluid volume (ECV). The use of ECV as an alternative scaling factor has the advantage of needing only the measurement of the half-time of the terminal exponential (between 2 and 4 h) in the plasma clearance curve of the filtration marker (for example, Cr-51-EDTA) and requires no measurements of height or weight. 10 
Methods
All patients referred for clinical measurement of GFR to a single nuclear medicine department over a period of several years up to the present were included. The only exclusion criteria were age o30 years and a poor exponential fit to the three data points from which the GFR was calculated (see below).
Slope-intercept GFR was measured from three samples taken at approximately 120, 180 and 240 min after injection of Cr-51-EDTA and scaled to a BSA of 1.73 m 2 (GFR/BSA).
Studies were rejected if the least squares exponential fit to these three points was o0.99. 11 The Brochner-Mortensen equation was used to correct for the one-compartment assumption. 12 GFR was also scaled to an ECV of 13 l, as described earlier (GFR/ECV), 13 l being the ECV of standard humans (analogous to a standard BSA of 1.73 m 2 ).
13
GFR/ECV was corrected for the one-compartment assumption using the equation described by Bird et al.
14
Patients were subdivided into two groups across a BMI boundary of 30 kg m À2 , defined by the World Health
Organization as the boundary between overweight and obesity.
Two forms of data analysis were used. First, patients were placed into 10-year age brackets (31-40, 41-50, 51-60, 61-70 and 470 years) and non-obese patients compared with obese patients in each bracket with respect to both GFR/BSA and GFR/ECV. Values in each category were expressed as mean±s.d. Within-category differences were assessed with Student's unpaired t-test with respect to obese versus non-obese and paired t-test with respect to GFR/BSA versus GFR/ECV.
Second, linear regression analysis was applied to noncategorized data to determine the relations between age and GFR/BSA and age and GFR/ECV for obese and non-obese patients, using Pearson's correlation coefficient to assess levels of significance. As there is wide recognition that the age-related decline in GFR is established by the age of 40 years, this analytical approach was limited to those aged 40 years or more.
Results
After excluding patients o30 years or with poor fits to the data (ro0.99), there were 589 and 149 non-obese and obese patient studies, respectively, for analysis. The clinical indications for GFR measurement could be subdivided into first planning for and monitoring the response to chemotherapy for cancer (B70%) and second investigating impaired renal function in patients without cancer (B30%), including a small minority concerned with the monitoring of renal function in patients receiving nephrotoxic drugs. In the first group with cancer, B21% of patients were obese compared with B25% in the non-cancer group. Of men in the study, B25% were obese compared with B21% of women. There was, in other words, no significant difference in the cross-section of clinical indications between obese and non-obese subjects.
From age 40 years, GFR/BSA and GFR/ECV in non-obese subjects decreased as functions of age at rates of 0.95 ml per min per 1.73 m 2 per year and 1.02 ml per min per 13 l per year, respectively. In comparison, the rates of decline in obese subjects were slightly but not significantly slower with corresponding rates of decline of 0.82 ml per min per 1.73 m 2 per year and 0.87 ml per min per 13 l per year. The details of this regression analysis are summarized in Table 1 .
From age-categorized analysis, there was again no difference between non-obese and obese patients ( Figure 1 ; Table 1 ). Thus, in non-obese patients aged 31-40 years, GFR/BSA and GFR/ECV were 92 ml per min per 1.73 m 2 and 95 ml per min per 13 l compared with 88 ml per min per 1.73 m 2 and 97 ml per min per 13 l in obese patients, whereas in patients aged 470 years, the corresponding values were 58 ml per min per 1.73 m 2 and 59 ml per min per 13 l in the non-obese compared with 57 ml per min per 1.73 m 2 and 59 ml per min per 13 l in the obese patients. No significant differences were observed between corresponding values scaled respectively to BSA and ECV.
Discussion
A limitation of this study is that the subjects were all patients, many with renal impairment. This would be expected to increase the scatter of the data, but, given the very similar levels of renal function in each age bracket between the 2 groups, only minimally influence the differences between average values. Standard deviations were also very similar between the two groups in each age GFR in obesity AM Peters et al bracket. Another limitation is that we have been unable to control for other diseases, such as cardiovascular disease and diabetes. The validity of the current database is nevertheless supported by rates of decline of GFR/BSA and GFR/ECV in both groups of patients that are very similar to the value of 0.91 ml per min per 1.73 m 2 per year reported for healthy potential kidney donors by Grewal and Blake. 9 Moreover, the similarity between GFR values between obese and non-obese patients in all age brackets would argue against any bias introduced as a result of possible differences in renal function between the two groups. Earlier studies have encountered problems by scaling to BSA in obese subjects, 7, 8 prompting the use of scaling to ECV in this study. Such studies have suggested that obese subjects have a normal GFR scaled to variables other than BSA. We found no evidence in this study to support this contention. Quite apart from the issue of scaling in obese patients, several investigators have criticized the use of BSA in general 15 and suggested alternatives, including not only ECV 10,13 but also total body water 16 and lean body mass. 7 The advantage of scaling to ECV compared with BSA in obese subjects was, however, shown to be only marginal in this study.
In conclusion, examination of the relation between age and GFR failed to reveal any adverse effect of obesity on agerelated decline in renal function, even though comorbid diseases associated with obesity were not taken into account. 
